Showing results (4101-4110 of 9,339) with videos related to
Sort By:
Pageof 934
Cancer Medicine|March 16, 2023
The role of facility and patient mix factors on recovery of screening and diagnostic mammography volumes following the initial COVID-19 pandemic waveSarah Lomahan, Garth H Rauscher, Anne Marie MurphyCancer Medicine|March 16, 2023
A novel prognostic model based on ferritin and nomogram-revised risk index could better stratify patients with extranodal natural killer/T-cell lymphomaXindi Liu, Yuanzheng Liang, Ziyuan Shen, et al.Cancer Medicine|March 20, 2023
Radiological lymph-node size improves the prognostic value of systemic inflammation index in rectal cancer with pathologically negative nodesShaoyong Peng, Xiaoxia Liu, Yingjie Li, et al.Cancer Medicine|March 20, 2023
A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive diseaseSarah J Storr, Victoria Hoskin, Radhika Aiyappa-Maudsley, et al.Cancer Medicine|March 1, 2023
Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinomaHaomin Wu, Shiqi Liu, Di Wu, et al.Cancer Medicine|March 19, 2023
Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching studyXiao Zhong, Xingwang Hu, Xue-Gong FanCancer Medicine|August 4, 2016
Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking methodYoshiko Saito, Ikuko Susukida, Yoshiro Uzuka, et al.Cancer Medicine|July 9, 2015
P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseasesMayumi Yoshimori, Honami Takada, Ken-Ichi Imadome, et al.Cancer Medicine|June 26, 2015
A new scoring system for predicting survival in patients with non-small cell lung cancerSteven E Schild, Angelina D Tan, Jason A Wampfler, et al.Cancer Medicine|July 16, 2016
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life settingKatia Cannita, Stefania Paradisi, Valentina Cocciolone, et al.Pageof 934